Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
To study the efficacy of sintilimab combined with anlotinib for perioperative non-small cell
lung cancer. To explore the clearance effect of sintilimab combined with anlotinib for
postoperative adjuvant therapy based on evaluating minimal residual disease.